SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 170 participants.
Also called NCT06054035
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 170 participants
- Registry
-
NCT06054035
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Germany
- Registry status
- Recruiting
Technical summary
Registry record NCT06054035. Randomized; double masking; primary purpose treatment. Start 2023-10-26 (actual); primary completion 2027-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
- Condition
- Type2diabetes
- Condition
- PreDiabetes
- Condition
- Renal Failure
- Intervention (Drug)
- Dapagliflozin (Forxiga®)
- Intervention (Drug)
- Placebo matching Dapaglifolzin
- Intervention (Behavioral)
- Lifestyle Intervention
- Lead sponsor
- University Hospital Tuebingen
- Collaborator
- German Federal Ministry of Education and Research
- Collaborator
- German Center for Diabetes Research
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct06054035- Content hash
3c9e5c02ef460ee02fbade366960cd9bb6316a446d451ccfdc7bf793b76a9eaf